I’m super excited about our new paper in @EUplatinum, “Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy” in @sowalsky lab @NIH@NCIResearchCtr @PCFScience
Patients diagnosed w/ aggressive, non-metastatic prostate cancer are at higher risk of recurrence after radical prostatectomy (RP). Post-op, some tumors progress to castration-resistant prostate cancer. Are there tumors that will respond to pre-surgical (neoadjuvant) therapies?